Determinants of Cognitive Impairment After Acute Coronary Syndrome (NCT00982176) | Clinical Trial Compass
CompletedNot Applicable
Determinants of Cognitive Impairment After Acute Coronary Syndrome
France49 participantsStarted 2009-09
Plain-language summary
The general purpose of the present pathophysiological study is to investigate the relation between cognitive impairment observed after an acute coronary syndrome and the presence of cerebral anatomo-functional abnormalities. This study will improve the investigators' understanding of the disease and will help in early diagnosis and prevention of vascular dementia in this population.
Who can participate
Age range
35 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male and female
* Age :30 to 65 years
* First acute coronary syndrome occurred 4 ± 1 months before the inclusion
* Able to understand the use of a pocket computer (palm)
* Able to use a pocket computer (palm)
* Able to give informed consent
* Affiliated to social insurance
Exclusion Criteria:
* Past medical history of stroke
* Diamox® injection contraindication
* Dementia
* History of major depression
* Aphasia
* Severe visual deficiency
* Contra-indication to brain MRI
* Contra-indication to HMPAO
* Contra-indication to Acetazolamide
* Patient under safeguard of justice
* For women, ineffective contraceptive method
* Breast-feeding or Pregnant women
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study was looking at white matter lesions in the brain after a heart attack — what are white matter lesions, and is this something my doctor would check for in my own care after an acute coronary syndrome?
2Since this trial was studying cognitive problems like difficulty with planning and decision-making after a coronary event, should I be getting any kind of cognitive or memory assessment as part of my follow-up care?
3The trial is already completed — does that mean results have been published, and if so, has my doctor seen findings that might be relevant to understanding my own risk of cognitive issues after my heart event?
4Given that this study was observational and focused on measuring brain changes rather than testing a treatment, are there any actual interventions or therapies my doctor would recommend to help protect my brain health after an acute coronary syndrome?
5Are there factors in my own history — like existing cardiovascular risk factors or signs of white matter changes on any prior brain imaging — that would make my doctor more or less concerned about cognitive decline following my coronary event?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
the extent of white matter vascular lesions (leuko encephalopathy) and impairment in executive functions